The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report ... forthcoming Phase 3 clinical trials for Orfoglipron.

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Companies including Biogen Inc. and Eli Lilly ... trials, numbers can go back in models and forecasts can be revised upwards quite significantly, quite quickly.” Firms developing Alzheimer’s ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report ... particularly in the SURMOUNT-1 Phase 3 trial. In this study, tirzepatide has ...